NCT00143351已完成3 期
Open Extension Study Evaluating the Long-term Efficacy, Safety, and Tolerability of Oral Ziprasidone in the Treatment of Resistant/Intolerant Schizophrenic Patients Who Have Acutely Responded to Ziprasidone in the Mozart Study
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.17 个研究点 分布在 1 个国家目标入组 75 人开始时间: 2003年6月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 75
- 试验地点
- 17
- 主要终点
- long-term efficacy of oral Ziprasidone in the maintenance treatment
研究概览
简要总结
To assess the long-term efficacy of oral Ziprasidone in the maintenance treatment of resistant schizophrenic subjects who have benefited from participation in the phase III ziprasidone study A1281039 (MOZART study), to assess the efficacy of ziprasidone in the relapse prevention of schizophrenia, to collect long-term data on safety and tolerability of oral Ziprasidone
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who have completed MOZART study and who are responders to Ziprasidone:
- •Responders: patients with a 20% or more reduction in the PANSS total score at the endpoint of the Mozart Study (recorded at V18 in the Mozart) as compared with the baseline value
- •Patients not hospitalised in an acute psychiatric service
- •Written, informed consent to participation.
- •Female patients of at risk of pregnancy must avoid to remain pregnant; if already used, an adequate method of contraception can be continued
排除标准
- •Psychiatric:
- •Subjects with a score of greater than or equal to 5 and an increase of at least 2 points (with respect to baseline value of MOZART study) at one of the following PANSS items: P7 (hostility), G8 (uncooperativeness) or G14 (poor control impulse)
- •Subjects with a score equal to 3 and an increase of at least 1 point (with respect to baseline value of MOZART study) at item 8 (suicide) of CDSS
- •Patients who, during MOZART study, have developed one of the following diseases will be excluded: (or patients who do not satisfy anymore one of the following general exclusion criteria of MOZART study)
- •Subjects with a history of clinically significant and/or currently relevant haematological, renal (including single kidney), hepatic, gastrointestinal, endocrine (except for current adequately treated hypo- or hyperthyroidism), pulmonary (excluding chronic bronchitis, mild emphysema or chronic obstructive pulmonary disease), dermatological, oncological, or neurological disease, excluding tardive dyskinesia but including all forms of epilepsy (febrile convulsions in childhood acceptable). The only subjects with known prior malignant disease who are eligible are those with cured prior skin cancer. Controlled Type II diabetes (glucose < 180 mg/100 ml at screening and baseline with dietary or oral hypoglycemic treatment) will not be considered a significant medical illness and would not exclude a subject from the study
- •Patients with a non stabilized somatic disease - Acute or chronic heart disease
- •Clinically significant ECG abnormalities
- •Subjects with QTc greater than or equal to 500 msec (subjects with QTc greater than or equal to 450 msec and < 500 msec should be discussed with the cardiologist) - Concomitant treatment with medications that prolong QTc interval (please review prescribing information of other treatments)
- •Subjects with serum K+ outside the normal range
- •History of seizure (should be discussed with the Sponsor)
- •Subject with any confirmed laboratory values that deviate from the upper or lower limits of normal prior to study entry, except for clinically insignificant deviations as determined by investigator
- •Pregnant or lactating women
- •Subjects who intend to donate blood or blood products during the 4 weeks prior to the study, during the study or in the 30 days after the study ends
- •Subjects unable or unlikely to follow the study protocol
- •Subjects with a history of neuroleptic malignant syndrome developing from the administration of antipsychotic compounds
- •Diagnosis of substance dependence using DSM-IV criteria (305.xx)
- •Positive urine drug screen at screening for amphetamines, cocaine or opioids
结局指标
主要结局
long-term efficacy of oral Ziprasidone in the maintenance treatment
次要结局
- To assess the efficacy of ziprasidone in the relapse prevention of schizophrenia To collect long-term data on safety and tolerability of oral Ziprasidone
研究者
研究点 (17)
Loading locations...
相似试验
已完成
3 期
Extension Study of Patients Successfully Treated by Ziprasidone in Study A1281031SchizophreniaNCT00174447Pfizer's Upjohn has merged with Mylan to form Viatris Inc.43
已完成
4 期
A Study of Ziprasidone for the Treatment of Psychosis in Patients Who Had Already Had Benefits From Ziprasidone Treatment in a Previous StudyPyschotic DisordersNCT00645320Pfizer's Upjohn has merged with Mylan to form Viatris Inc.75
已完成
3 期
Safety and Tolerability of Ziprasidone in Children and Adolescents With Bipolar I Disorder (Manic or Mixed)Bipolar DisorderNCT00265330Pfizer's Upjohn has merged with Mylan to form Viatris Inc.169
终止
3 期
Safety And Tolerability Of Ziprasidone In Adolescents With SchizophreniaSchizophreniaNCT00265382Pfizer's Upjohn has merged with Mylan to form Viatris Inc.221
撤回
3 期
Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder (Manic Or Mixed)Bipolar DisorderNCT01124877Pfizer's Upjohn has merged with Mylan to form Viatris Inc.